Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.

Mersiha Hadziahmetovic, Billy W. Loo, Robert D. Timmerman, Nina A. Mayr, Jian Z. Wang, Zhibin Huang, John C. Grecula, Simon S. Lo

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), has emerged as one of the standard treatment options for stage I non-small cell lung cancer (NSCLC), mainly in medically inoperable patients. Its use has also been explored in operable patients. A large body of experience, either from retrospective studies or clinical trials, has been accumulated over the years and more is known about the radiobiology, cancer biology, technical aspects, clinical outcomes, and toxicities of SBRT. This article provides updates of these aspects of SBRT for stage I NSCLC.

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalDiscovery Medicine
Volume9
Issue number48
StatePublished - May 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.'. Together they form a unique fingerprint.

  • Cite this